 |
|
Researcher Profile - Georg Winterer |
|
|
|
| First Name: | Georg | | Last Name: | Winterer | | Affiliation: | Charite Berlin | | City: | Berlin | Country/Territory: | Germany | | Email Address: |  |
Disclosure:
(view policy) |
Member reports the following financial or other potential conflicts of interest: [Last Modified: 29 October 2012]
see: www.pi-pharmaimage.com |
|
|
View all comments by Georg Winterer
|
Drug abuse, Schizophrenia
|
Brain imaging, Electrophysiology, Genetics, Pharmacology, Clinical trials
|
University, Medical hospital
|
2012- Senior Researcher Charite Berlin BioCog Program
2007-2013 Coordinator: National DFG priority program: Nicotine - molecular and physiological effects in CNS (www.nicotine-research.com)
2009-2012 Senior Researcher Coplogne Center for Genomics, University of Cologne/Inst. of Neurosciences & Biophysics, Helmholtz Research Center Jülich
2006-2009 Full Professor of Psychiatry/Clinical Director Dept. of Psychiatry, Univ. of Düsseldorf/Inst. of Neurosciences & Biophysics, Helmholtz Research Center Jülich
2003-2005 Consultant Psychiatrist, Dept. of Psychiatry, Univ. of Mainz/
1998-2003 Research Fellow, National Institute of Mental Health, Clinical Brain Disorders Branch
2001 Habilitation (PhD) Free University of Berlin
1995-1998 Postdoc, Lab. of Psychophysiology, Dept. of Psychiatry, Free Univ. Berlin
1990-1995 Clinician and Junior Research Fellow, Dept. for Psychiatry, Free Univ. Berlin
|
1. Quednow, B.B., Brinkmeyer, J., Mobascher, A., Nothnagel, M., Musso, F., Gründer, G., Savary, N., Petrovsky, N., Frommann, I., Lennertz, L., Spreckelmeyer, K.N., Wienker, T.F., Dahmen, N., Thuerauf, N., Clepce, M., Kiefer, F., Majic, T., Mössner, R., Maier, W., Gallinat, J., Diaz-Lacava, A., Toliat, M.R., Thiele, H., Nürnberg, P., Wagner, M., Winterer, G. (2012) Schizophrenia risk polymorphisms in the TCF4 gene interact with smoking in the modulation of auditory sensory gating. Proc. Natl. Acad. Sci. USA 109:6271-6.
2) Winterer, G., Gallinat, J., Brinkmeyer, J., Musso, F., Kornhuber, J., Thuerauf, N., Rujescu, D., Favis, R., Sun, Y., Franc, M.A., Ouwerkerk-Mahadevan, S., Janssens, L., Timmers, M., Streffer, J.R. (2012) Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology (Epub ahead of print)
3. Musso, F., Brinkmeyer, J., Ecker, D., London, M.K., Thieme, G., Warbrick, T., Wittsack, H.-J., Saleh, A., Greb, W., de Boer, P., Winterer, G. (2011) A Novel Ketamine Effects on Brain Function: Simultaneous fMRI/EEG during a Visual Oddball Task. Neuroimage 58:508-25
4. Brinkmeyer, J., Mobascher, A., Musso, F., Schmitz, M., Wagner, M., Gründer, G., Spreckelmeyer, K.N., Wienker, T., Diaz Lacava, A., Holler, D., Dahmen, N., Thuerauf, N., Clepce, M., Kiefer, F., de Millas, W., Gallinat, J., Winterer, G. (2011) P50 sensory gating and smoking in the general population. Addiction Biol. 16:485-98
5. Aubin, H.-J., Rollema, H., Svensson, T.H., Winterer, G. (2012) Smoking, Quitting and Psychiatric Disease: A Review. Neurosci. & Biobehav. Rev. 36:271-84
6. Rolls, E.T., Loh, M., Deco, G., Winterer, G. (2008) Schizophrenia and computational models of dopamine modulation in the prefrontal cortex. Nature Reviews Neuroscience 9:696-709
7. Javitt, D., Spencer, K.M., Thaker, G.K., Winterer, G., Hajos, M. (2008) Biomarkers for schizophrenia – Novel approaches to diagnosis and treatment. Nature Reviews Drug Discovery 7:68-83.
8. Winterer, G., Musso, F., Konrad, A., Vucurevic, G., Stoeter, P., Sander, T., Gallinat, J. (2007) Association of attentional network function and exon 5 variations of the CHRNA4 gene. Human Molecular Genetics 16:2165-2174
9. Winterer, G., Coppola, R., Goldberg, T.E., Egan, M.F., Jones, D.W., Sanchez, C.E., Weinberger, D.R. (2004) Prefrontal broadband noise, working memory & genetic risk for schizophrenia. Am. J. Psychiatry 161(3):1-11
10. Winterer, G., Egan, M.F., Goldberg, T.E., Coppola, R., Weinberger, D.R. P300 and ge-netic risk for schizophrenia. Arch. Gen. Psychiatry 60:158-1167, 2003.
|
A large multicentric phase-1/2a study on the differential effects of cognition enhancers on surrogate measures of cognition/cognitive measures in heakthy volunteers and schizophrenia patients - collaboration between a network of industry R&D and academia |
I am pragmatic - there are promising hyopthesis but not a leading hypothesis. Let´s see what works |
if someone comes up with a drug that works, i.e., that has a clinically relevant effect on cognitive performance/negative symptoms in schizophrenia, he or she can claim victory. Everything else is l´art pour l´art. |
Looking at medical/drug conditions that mimick schizophrenia symptoms |
|
|
|
|
|
